Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have earned a consensus recommendation of “Hold” from the seventeen analysts that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $22.25.

Several equities analysts have recently weighed in on MYGN shares. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Cowen and Company reiterated a “market perform” rating and set a $19.00 price objective on shares of Myriad Genetics in a report on Tuesday, March 28th. Jefferies Group LLC reiterated a “hold” rating and set a $21.00 price objective (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Deutsche Bank AG lifted their price objective on Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Finally, J P Morgan Chase & Co reiterated an “underweight” rating and set a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/21/myriad-genetics-inc-mygn-given-average-rating-of-hold-by-brokerages-2.html.

Myriad Genetics (NASDAQ MYGN) opened at 24.32 on Friday. The firm has a market cap of $1.66 billion, a P/E ratio of 51.97 and a beta of 0.32. Myriad Genetics has a one year low of $15.15 and a one year high of $32.54. The stock has a 50 day moving average price of $24.27 and a 200-day moving average price of $20.02.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The business had revenue of $196.90 million for the quarter, compared to analysts’ expectations of $188.89 million. Analysts predict that Myriad Genetics will post $1.01 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. bought a new position in Myriad Genetics during the first quarter valued at $112,000. Creative Planning raised its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares during the period. State of Alaska Department of Revenue bought a new position in Myriad Genetics during the first quarter valued at $144,000. Karp Capital Management Corp bought a new position in Myriad Genetics during the first quarter valued at $223,000. Finally, Opus Point Partners Management LLC bought a new position in Myriad Genetics during the fourth quarter valued at $232,000.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.